EXELIOM
Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies. Exeliom develops a new class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system. The company was founded in 2016 and is headquartered in Dijon, France.
EXELIOM
Industry:
Biopharma Biotechnology Health Care Pharmaceutical
Founded:
2016-01-01
Address:
Dijon, Bourgogne, France
Country:
France
Website Url:
http://www.nextbiotix.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
7 M EUR
Technology used in webpage:
Google Apps For Business Microsoft Azure DNS Wix Wix DNS
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Current Advisors List
Current Employees Featured
Founder
Investors List
INRA
INRA investment in Series A - Exeliom
Sofimac Innovation
Sofimac Innovation investment in Series A - Exeliom
Cap Innov'Est
Cap Innov'Est investment in Series A - Exeliom
Biocodex
Biocodex investment in Series A - Exeliom
Auriga Partners
Auriga Partners investment in Series A - Exeliom
Official Site Inspections
http://www.nextbiotix.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.171
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Exeliom"
Exeliom - Crunchbase Company Profile & Funding
Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people …See details»
Nextbiotix becomes Exeliom Biosciences
Nextbiotix becomes Exeliom Biosciences. Back to news. #biotech #crohn'sdisease #clinicalstudy #milestones #immunotherapy #microbiome #livebiotherapeutics. Oct 19, 2023. Exeliom …See details»
Exeliom Biosciences - LinkedIn
Exeliom Biosciences is a clinical-stage biotechnology company developing next-generation immunotherapies in immuno-oncology and immuno-inflammation. Our novel candidates harness...See details»
Nextbiotix SAS - life-sciences-europe.com
Based in Dijon, with offices in Paris (France), NEXTBIOTIX is a biopharmaceutical company developing Live Biotherapeutics using commensal bacteria as drugs to treat major …See details»
exeliom
Exeliom Biosciences is a clinical-stage biotechnology company developing next-generation therapies in immuno-oncology and immuno-inflammation. in indications where dysregulated immunity hampers efficacy, including …See details»
Nextbiotix - VentureRadar
Nexbiome therapeutics is a private incubator of microbiome biotech companies. Our mission is to identify the best research projects and turn them into biotech companies that will bring …See details»
Exeliom Biosciences Announces Series A Extension and …
Jul 3, 2023 · Exeliom Biosciences (formerly Nextbiotix), a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunomodulation axis to develop next-generation immunotherapies, …See details»
Exeliom Biosciences closes its Series A funding at €24 …
Jul 3, 2023 · Paris-based Exeliom Biosciences (formerly Nextbiotix), a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunomodulation axis to develop next-generation …See details»
Nextbiotix - Biotech.info
“We are committed to developing a new generation of medicines: monoclonal microbial therapies. We will use our breakthrough translational approach, our unique relationships with our …See details»
Nextbiotics - Crunchbase Company Profile & Funding
Nextbiotics is a biotechnology platform that engineers viruses for good. Where is Nextbiotics's headquarters? Nextbiotics is located in San Francisco, California, United States. Who invested …See details»
Exeliom - Funding, Financials, Valuation & Investors - Crunchbase
Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs.See details»
Exeliom Biosciences - Craft
Exeliom Biosciences (formerly Nextbiotix) is a biotechnology company developing monoclonal microbial therapies. Its lead candidate, a mono-strain product, uses Faecalibacterium …See details»
News - exeliom
France-based Exeliom Biosciences (formerly Nextbiotix) is exploring these possibilities. The biotech is developing single microbial strains intended to safely act on immunomodulatory …See details»
€7m for French microbiome start-up - European Biotechnology …
Jul 6, 2018 · Microbiome start-up Nextbiotix raised € 7m in a Series A round. The Paris-based biotech uses commensal bacteria as drugs to treat major inflammatory bowel diseases. …See details»
Microbiome start-up Nextbiotix nets €7m to address
Jul 12, 2018 · French-based biotech start-up Nextbiotix has successfully raised €7m in a Series A financing round, to develop microbiome-based approaches that address inflammatory bowel …See details»
Nextbiotix's Lead IBD Therapy Candidate Receives €7M in Funding
Jul 23, 2018 · Nextbiotix has secured €7 million ($8.2 million) in funding to develop NBX1650, the company’s lead bacterial candidate for the treatment of inflammatory bowel disease (IBD). …See details»
Exeliom - Contacts, Employees, Board Members, Advisors & Alumni
Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs.See details»
Nextbiotix raises €7m in a Series A round to tackle inflammatory …
Jul 6, 2018 · PRESS RELEASE - Nextbiotix, a microbiome biotech company developing innovative Live Biotherapeutics using commensal bacteria as drugs to treat major …See details»
Nextbiotix réussit une première levée de 7 M€ pour s’attaquer aux ...
Jul 6, 2018 · COMMUNIQUE DE PRESSE - Nextbiotix, une nouvelle startup dans le domaine du microbiome, développe une approche mono-souche pour traiter les maladies inflammatoires …See details»
Microbiome startup Nextbiotix raises €7M to tackle inflammatory …
Jul 5, 2018 · Nextbiotix has raised €7 million ($8 million) to develop a bacterial treatment for inflammatory bowel diseases. The series A round will support work to rebalance the gut …See details»